KENNETH EZENWA: Open Payments
NPI 1003379959 · CANYON COUNTRY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,600 in 68 payments from 12 companies in 2025. Trend: 2023 $368 · 2024 $570 · 2025 $1,600
Food & beverage: $1,595Education: $5
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 20 | $417 |
| Teva Pharmaceuticals USA, Inc. | 9 | $216 |
| Janssen Pharmaceuticals, Inc | 9 | $212 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $181 |
| ABBVIE INC. | 6 | $147 |
| Alkermes, Inc. | 3 | $96 |
| E.R. Squibb & Sons, L.L.C. | 4 | $78 |
| Neurocrine BioSciences, Inc. | 3 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Lundbeck LLC | 3 | $60 |
Products named: REXULTI, INVEGA SUSTENNA, CAPLYTA, AUSTEDO XR, VRAYLAR, ABILIFY ASIMTUFII, COBENFY, INGREZZA.
Industry payments across CA — which companies pay providers there.
